HER2 in Colorectal Carcinoma: Are We There yet?
Sign Up to like & getrecommendations! Published in 2020 at "Surgical pathology clinics"
DOI: 10.1016/j.path.2020.05.007
Abstract: HER2 (ERBB2) is a member of the ERBB family of receptor tyrosine kinases and functions to drive signaling in the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR pathways. Overall, approximately 2-3% of CRCs exhibit ERBB2 amplification. Multiple phase II… read more here.
Keywords: her2 colorectal; targeted therapy; colorectal carcinoma; carcinoma yet ... See more keywords
Combination therapy with afatinib and bevacizumab in an EGFR-mutated non-small cell lung cancer patient with acquired ERBB2 amplification
Sign Up to like & getrecommendations! Published in 2021 at "Medicine"
DOI: 10.1097/md.0000000000024380
Abstract: Abstract Introduction: Acquired resistance to reversible EGFR tyrosine kinase inhibitors remains a significant obstacle, and acquired ERBB2 amplification is the most common “bypass” mechanism. For patients with sensitizing EGFR mutation who experience resistance via ERBB2… read more here.
Keywords: combination therapy; lung; therapy afatinib; amplification ... See more keywords
Abstract 5536: Landscape and analysis of ERBB2 amplification and short variant mutations in large-scale Chinese patients with colorectal cancer
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5536
Abstract: Background: Human epidermal growth factor receptor 2 (ERBB2) amplification is a rapidly emerging therapeutic target in CRC, in spite of a relatively low incidence. While ERBB2 amplification has been considered as a critical biomarker to… read more here.
Keywords: colorectal cancer; mutation; erbb2 amplification; chinese patients ... See more keywords
Detection and description of ERBB2 amplification using circulating cell free tumor DNA (ctDNA) genomic analysis in metastatic colorectal cancer (mCRC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.4_suppl.661
Abstract: 661Background: ERBB2 amplification (HER2amp) is evolving as a distinct subset of mCRC with therapeutic implications. Although seen in 3-4% of mCRC in tumor tissue, little is known about occurrence of HER2amp in ctDNA. The purpose… read more here.
Keywords: ctdna; mcrc; erbb2 amplification; her2amp ... See more keywords
Acral lentiginous melanoma with HER2/ErbB2 amplification
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Dermatology"
DOI: 10.1684/ejd.2021.4115
Abstract: EJD, vol. 31, n◦ 4, July-August 2021 suggests that retrograde spread of the virus from a primary nipple condyloma is possible. The spread may also be due to leakage of HPV to the blood circulation… read more here.
Keywords: melanoma her2; dermatology; lentiginous melanoma; her2 erbb2 ... See more keywords
Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.986674
Abstract: ERBB2 amplification is one of the most important and mature targets for HER2-targeted drug therapy. Somatic mutations of ERBB2 in the tyrosine kinase domain have been studied extensively, and play a role in response to… read more here.
Keywords: erbb2 fusion; erbb2 amplification; solid tumors; erbb2 fusions ... See more keywords
Putative Clinical Potential of ERBB2 Amplification Assessment by ddPCR in FFPE-DNA and cfDNA of Gastroesophageal Adenocarcinoma Patients
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14092180
Abstract: Simple Summary Gastroesophageal adenocarcinoma (GEA) has a poor prognosis. However, since the HER2 positive subgroup could benefit from trastuzumab targeted therapy, considerable effort has been spent in determining the HER2 status in these patients. To… read more here.
Keywords: ddpcr; gastroesophageal adenocarcinoma; erbb2 amplification; cfdna ... See more keywords
ERBB2 Amplification as a Predictive and Prognostic Biomarker in Upper Tract Urothelial Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15092414
Abstract: Simple Summary Upper tract urothelial carcinomas (UTUCs) occur in about 5–10% of all urothelial carcinomas and are frequently discovered in high-stage disease. We aimed to evaluate human epidermal growth factor receptor 2 (ERBB2) protein expression… read more here.
Keywords: oncology; erbb2 amplification; tract urothelial; amplification ... See more keywords